Research programme: cystic fibrosis therapeutic - RetrophinAlternative Names: RE-013
Latest Information Update: 16 Jul 2016
At a glance
- Originator Retrophin
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cystic-fibrosis in USA
- 28 May 2012 Early research in Cystic fibrosis in USA (unspecified route)